Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UBE2M | P61081 | 5/20 | 0.49 |
| ▸ | DCUN1D1 | Q96GG9 | 5/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | LTA4H | P09960 | 2/20 | 0.44 |
| ▸ | CCR5 | P51681 | 4/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | PTBP1 | P26599 | 1/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1450268 | 0.91 | LTA4H (0.46) | UBE2MDCUN1D1LMNALTA4HCCR5 | |
| Hydrochloric Acid SCHEMBL1449383 | 0.91 | CCR5 (0.45) | UBE2MDCUN1D1LMNALTA4HCCR5 | |
| Hydrochloric Acid SCHEMBL1449302 | 0.90 | UBE2M (0.49) | UBE2MDCUN1D1LMNALTA4HCCR5 | |
| Hydrochloric Acid SCHEMBL1450198 | 0.90 | LTA4H (0.44) | UBE2MDCUN1D1LMNALTA4HCCR5 | |
| Hydrochloric Acid SCHEMBL1449400 | 0.90 | UBE2M (0.49) | UBE2MDCUN1D1LMNALTA4HCCR5 | |
| Hydrochloric Acid SCHEMBL1449771 | 0.90 | LTA4H (0.44) | UBE2MDCUN1D1LMNALTA4HCCR5 | |
| Hydrochloric Acid SCHEMBL1450161 | 0.89 | LMNA (0.52) | UBE2MDCUN1D1LMNALTA4HCCR5 | |
| SCHEMBL1449549 | 0.89 | LTA4H (0.43) | UBE2MDCUN1D1LMNALTA4HCCR5 | |
| Hydrochloric Acid SCHEMBL1448845 | 0.89 | LTA4H (0.47) | UBE2MDCUN1D1LMNALTA4HCCR5 | |
| Hydrochloric Acid SCHEMBL1448692 | 0.88 | LTA4H (0.51) | UBE2MDCUN1D1LMNALTA4HCCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7910741-B2 | Nitrogen-containing heterocyclic derivatives and drugs containing the same as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-03-22 | — | — | US | disclosed |
| US-20060178399-A1 | Nitrogen-containing heterocyclic derivatives and drugs containing the same as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-08-10 | — | — | US | disclosed |
| EP-1604981-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-12-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060178399-A1 | Nitrogen-containing heterocyclic derivatives and drugs containing the same as the active ingredient | HLA-DRB1, ELANE, MMP8 | UBE2M 3256/4885DCUN1D1 3114/4885LMNA 4835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.